Skip to main content
SpringerLink
Log in

Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma

  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Background

Antiviral treatments for hepatitis B virus (HBV) are not established in patients with HBV-related hepatocellular carcinoma (HCC).

Aim

To investigate the safety and efficacy of lamivudine (LAM) in patients with HBV-related HCC who were treated with radiofrequency ablation (RFA).

Methods

RFA-treated patients with HBV-related HCC were retrospectively divided into those who received LAM (LAM group) and those who did not (nontreatment group). The first-year changes in serum alanine aminotransferase (ALT), total bilirubin (TBIL), and albumin (ALB) levels were compared in corresponding subsets based on Child-Pugh classification (Mann–Whitney U test) and between one-to-one matched pairs (Wilcoxon signed rank test), who were selected on the basis of their propensity scores for receiving LAM. Overall and recurrence-free survival was also compared.

Results

Complete ablation of HCC was achieved in 104 patients with HBV-related HCC between January 2000 and December 2005. LAM was administered to 33 patients after RFA. Serum HBV-DNA became negative by TMA method in 24 (73%) patients. Four patients showed redetection of HBV-DNA with ALT elevation. Subset analysis based on initial Child-Pugh class and paired analysis with matching revealed significant decreases in ALT and bilirubin levels and increases in ALB levels in the first year in the LAM group (ΔALT = −17, ΔALB = +0.3, and ΔTBIL = −0.2) compared with controls (ΔALT = +5, ΔALB = ±0.0, and ΔTBIL = +0.3). Overall survival and recurrence-free survival did not differ between the two groups. No specific adverse effect was observed in the LAM group.

Conclusion

LAM after RFA for HBV-related HCC was safe and improved liver function. Further studies are needed to evaluate its effect on survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995;22:1027–33

    Article  PubMed  CAS  Google Scholar 

  2. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B, C: a prospective study of 251 patients. Hepatology 1995;21:650–5

    PubMed  CAS  Google Scholar 

  3. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930–8

    Article  PubMed  CAS  Google Scholar 

  4. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005;103:1201–9

    Article  PubMed  Google Scholar 

  5. Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995;1:73

    PubMed  CAS  Google Scholar 

  6. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655–61

    PubMed  CAS  Google Scholar 

  7. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002;62 Suppl 1:64–8

    Article  PubMed  CAS  Google Scholar 

  8. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235–40

    Article  PubMed  Google Scholar 

  9. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122–30

    Article  PubMed  Google Scholar 

  10. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004;127:S159–66

    Article  PubMed  Google Scholar 

  11. Omata M. Treatment of chronic hepatitis B infection. N Engl J Med 1998;339:114–5

    Article  PubMed  CAS  Google Scholar 

  12. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207–10

    Article  PubMed  CAS  Google Scholar 

  13. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411–6

    Article  PubMed  CAS  Google Scholar 

  14. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–31

    Article  PubMed  CAS  Google Scholar 

  15. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808–16

    Article  PubMed  CAS  Google Scholar 

  16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800–7

    Article  PubMed  CAS  Google Scholar 

  17. Yoshida H, Shiratori Y, Moriyama M, et al., for the IHIT (Inhibition of Hepatocarcinogenesis by Interferon Therapy) Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174–81

    Google Scholar 

  18. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051–55

    Article  PubMed  CAS  Google Scholar 

  19. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299–306

    PubMed  Google Scholar 

  20. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963–7

    PubMed  CAS  Google Scholar 

  21. Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006;44:1518–27

    Article  PubMed  CAS  Google Scholar 

  22. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527–32

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, Japan, 113-8655

    Hideo Yoshida, Haruhiko Yoshida, Eriko Goto, Takahisa Sato, Takamasa Ohki, Ryota Masuzaki, Ryosuke Tateishi, Tadashi Goto, Shuichiro Shiina, Takao Kawabe & Masao Omata

Authors
  1. Hideo Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haruhiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eriko Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takahisa Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takamasa Ohki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ryota Masuzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryosuke Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tadashi Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shuichiro Shiina
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takao Kawabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masao Omata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Yoshida.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshida, H., Yoshida, H., Goto, E. et al. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Int 2, 89–94 (2008). https://doi.org/10.1007/s12072-007-9020-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-007-9020-7

Keywords

Search

Navigation